SEC Form 4 · accession 0001140361-16-082543
OncoMed Pharmaceuticals Inc · OMED
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John A. Lewicki
Officer — EVP, Research & Development
Period of report
Oct 9, 2016
Accepted (ET)
Oct 11, 2016 · 9:44 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001302573
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Oct 9, 2016 | A | 12,500 | $0.00 | A | 31,636 | D | |
| Common StockF3 | holding | — | — | — | 84,815 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Restricted stock units ("RSUs"). The reporting person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof.
- F2Includes 27,500 restricted stock units and 1,298 shares acquired under the Issuer's Employee Stock Purchase Plan on February 29, 2016.
- F3The shares are held by John Allan Lewicki and Jenniffer Joan Lewicki, Trustees of the Lewicki Family Trust dated December 6, 2000.